Table Graph
      published meta-analysis   sensitivity analysis   studies

Immunostimulants drugs in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsSekine (PLACOVID), 2021 2.14 [0.70; 6.58] 2.14[0.70; 6.58]Sekine (PLACOVID), 202110%160NAnot evaluable death D28detailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Li, 2020 0.59 [0.22; 1.59] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Raman, 2021 0.49 [0.02; 15.10] RECOVER, 2021 1.09 [0.38; 3.13] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Tabarsi, 2020 1.10 [0.45; 2.67] 0.93[0.68; 1.27]AlQahtani, 2020, Kalil (ACTT-3), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, Sekine (PLACOVID), 2021, Tabarsi, 2020100%2,160moderatelow death or transfer to ICUdetailed resultsLopardo, 2021 0.65 [0.35; 1.22] 0.65[0.35; 1.22]Lopardo, 202110%241NAnot evaluable deathsdetailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] CAPSID, 2021 0.84 [0.28; 2.50] CP-COVID-19, 2021 3.20 [0.62; 16.39] Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Li, 2020 0.59 [0.22; 1.59] Lopardo, 2021 0.57 [0.24; 1.37] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rahmani, 2020 0.29 [0.05; 1.56] Raman, 2021 0.49 [0.02; 15.10] Rasheed, 2020 0.13 [0.01; 1.09] RECOVER, 2021 1.09 [0.38; 3.13] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Tabarsi, 2020 1.10 [0.45; 2.67] 0.86[0.70; 1.06]AlQahtani, 2020, CAPSID, 2021, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021, Tabarsi, 2020189%4,781lowlow deaths (time to event analysis only)detailed resultsCP-COVID-19, 2021 3.20 [0.62; 16.39] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] PlasmAr, 2020 0.93 [0.47; 1.85] 1.28[0.68; 2.41]CP-COVID-19, 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020311%1,403lownot evaluable clinical deteriorationdetailed resultsCAPSID, 2021 0.63 [0.29; 1.40] 0.63[0.29; 1.40]CAPSID, 202110%105NAnot evaluable clinical improvementdetailed resultsCAPSID, 2021 1.58 [0.71; 3.49] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Li, 2020 1.40 [0.79; 2.49] Lopardo, 2021 1.61 [0.75; 3.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] 1.17[0.95; 1.44]CAPSID, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Kalil (ACTT-3), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021953%2,234moderateserious clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] Li, 2020 2.27 [0.90; 5.72] 1.33[0.63; 2.83]Kalil (ACTT-3), 2021, Li, 2020264%1,072moderatenot evaluable clinical improvement (28-day)detailed resultsLi, 2020 1.42 [0.65; 3.10] O’Donnell, 2021 1.38 [0.73; 2.61] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] 1.41[0.82; 2.45]Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021465%546moderatenot evaluable clinical improvement (7-day)detailed resultsLi, 2020 0.98 [0.27; 3.58] 0.98[0.27; 3.58]Li, 202010%103NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] Rahmani, 2020 3.41 [1.33; 8.73] 1.23[0.98; 1.54]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020755%1,775moderateserious hospital dischargedetailed resultsRahmani, 2020 3.44 [0.64; 18.49] 3.44[0.64; 18.49]Rahmani, 202010%66NAnot evaluable mechanical ventilationdetailed resultsAlQahtani, 2020 0.67 [0.22; 2.02] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] Rahmani, 2020 0.29 [0.05; 1.56] Tabarsi, 2020 1.49 [0.59; 3.78] 0.96[0.63; 1.45]AlQahtani, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Tabarsi, 202070%826moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] 0.66[0.25; 1.72]CP-COVID-19, 202110%100NAnot evaluable radiologic improvement (14-day)detailed resultsTabarsi, 2020 2.33 [0.45; 12.00] 2.33[0.45; 12.00]Tabarsi, 202010%84NAnot evaluable viral clearance detailed resultsCP-COVID-19, 2021 1.12 [0.16; 7.84] Raman, 2021 36.42 [10.85; 122.18] 6.97[0.23; 210.35]CP-COVID-19, 2021, Raman, 2021289%200moderatenot evaluable viral clearance by day 14detailed resultsCP-COVID-19, 2021 1.51 [0.33; 6.94] Raman, 2021 36.42 [10.85; 122.18] 7.68[0.34; 173.70]CP-COVID-19, 2021, Raman, 2021290%200moderatenot evaluable ICU admissiondetailed resultsCP-COVID-19, 2021 0.82 [0.35; 1.91] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Lopardo, 2021 0.67 [0.35; 1.28] Rahmani, 2020 0.37 [0.14; 1.00] Tabarsi, 2020 0.56 [0.18; 1.74] 0.62[0.42; 0.92]CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Lopardo, 2021, Rahmani, 2020, Tabarsi, 202060%571moderatenot evaluable serious adverse eventsdetailed resultsO’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] Raman, 2021 0.49 [0.02; 15.10] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] 1.19[0.81; 1.76]O’Donnell, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021552%2,792lownot evaluable superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable adverse eventsdetailed resultsRaman, 2021 1.36 [0.56; 3.30] Sekine (PLACOVID), 2021 1.08 [0.85; 1.38] 1.10[0.87; 1.39]Raman, 2021, Sekine (PLACOVID), 202120%260moderatenot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2025-03-09 15:48 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons